More than 1,300 people who have been affected by acquired immune deficiency syndrome (AIDS) gathered at the National AIDS Memorial in San Francisco on Dec. 1 to commemorate World AIDS Day. During two days of events, family and friends paid tributes to those lost to the disease, while inspiring remembrance…

Two presentations at the 2016 American Society of Hematology Annual Meeting (ASH) highlight ongoing treatment advances for hemophilia B. The data suggest that life with hemophilia could soon become easier to manage. Long-acting replacement therapy The ASH meeting, held in San Diego on Dec. 3-6, was a platform for CSL Behring to…

Researchers have successfully applied a potential gene therapy for hemophilia B based on the genome editing properties of the CRISPR/Cas9 system. The results of this study using mice were presented recently at the 58th Annual American Society of Hematology Meeting and Exposition in San Diego, Calif. Hemophilia B is a disease…

Researchers have developed a biodegradable capsule to deliver a protein missing in patients with hemophilia B, according to a new study published in the International Journal of Pharmaceutics. If it proves to be successful, this capsule may provide a cheaper and less painful option to injections or infusions. The…

A combination of drugs acting on different points of the pain pathway may be beneficial in reducing joint pain in people with hemophilia, according to a review article published in the journal Blood Coagulation and Fibrinolysis.

Treating a spontaneous brain hemorrhage in patients with hemophilia may be less risky if the acute hematoma is converted into a chronic hematoma, which is easier to treat, according to a case report published in the International Journal of Surgery Case Reports. In the report, “Spontaneous Intracerebral Hemorrhage In Hemophiliacs…

Four patients taking part in a Phase 3 clinical trial of Roche’s investigational hemophilia drug emicizumab (ACE910) have experienced serious thrombotic events, blood clots that cause partial or total obstruction, Reuters reported this week. The patients were being treated for breakthrough bleeding. According to Reuters, a Roche spokesperson said…

uniQure, a company specializing in human gene therapy, will present clinical data from a Phase 1/2 dose-escalating study of AMT-060 in adults with hemophilia B at the upcoming 58th American Society of Hematology Annual Meeting (ASH 2016), to be held in San Diego, Calif., in Dec.3-6. The…

A recent survey has shown that the use of appropriate standardized outcome measures of hemophiliac patient treatments in routine clinical practice are not the norm. But implementing these measures could promote more effective personalized therapeutic approaches and reduce treatment-related costs. Hemophilia is a complex disease with a major impact on the…

A research team from the departments of biochemistry and pathology at the University of Pennsylvania’s School of Dental Medicine has found a successful technique using genetic engineering to coax lettuce and tobacco plants to produce foreign proteins in their leaves. The applications include producing the human clotting factor to make…